<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071639</url>
  </required_header>
  <id_info>
    <org_study_id>2019238</org_study_id>
    <nct_id>NCT04071639</nct_id>
  </id_info>
  <brief_title>Symptomatic Therapy for Patients With Huntington's Disease</brief_title>
  <official_title>Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the previous symptomatic treatment of Chinese HD patients, this study intends to&#xD;
      further optimize the treatment regimen of Chinese HD patients so as to further improve the&#xD;
      prognosis of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate symptomatic treatment regimen efficacy based on&#xD;
      different disease stages. We previously used symptomatic treatment on Chinese HD patients and&#xD;
      most of them got improved both in the motor symptoms and life quality. So this study intends&#xD;
      to further optimize the treatment regimen, and set a control group to further evaluate the&#xD;
      treatment efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Case group use Deutetrabenazine，Risperidone，Zoloft and Idebenone(depending on demand and symptom).&#xD;
Control group use Haloperidol，Risperidone，Zoloft and Idebenone(depending on demand and symptom).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Unified Huntington's Disease Rating Scale</measure>
    <time_frame>Five years</time_frame>
    <description>The Unified Huntington's Disease Rating Scale consist of four subscales, including motor(0-124), MMSE (0-30), psychiatric (0-176), and functional domains(1-13). Four subscale scores are summed to compute a total score. Higher motor and psychiatric scores represent worse outcomes but higher MMSE score and functional scores indicate good outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>Five years</time_frame>
    <description>Brain MRI is used to assess the atrophy of caudate nucleus and cortex in HD patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild to moderate HD patients receive medicine treatment with different doses of Deutetrabenazine(Austedo), Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Zoloft should be taken 50mg once in the morning and Risperidone 1mg once at night. Deutetrabenazine(Austedo) should be taken 6mg once a day, or increase dose according to AUSTEDO® tablets Prescribing Information. Idebenone should be taken 30mg three times a day. Study drug can be taken irrespective of meals. Duration:5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild to moderate HD patients receive medicine treatment with different doses of Haloperidol, Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Haloperidol should be taken 0.5mg~1mg three times a day. The administration of Zoloft, Risperidone and Idebenone are same as group 1. Study drug can be taken irrespective of meals. Duration:5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol 2Mg Tab</intervention_name>
    <description>Haloperidol take 0.5mg~2mg three time a day.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Haloperidol Tables, H31021234</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone 1Mg Tab</intervention_name>
    <description>Risperidone take 1mg once at night.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Risperidone, H20010309</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoloft 50Mg Tablet</intervention_name>
    <description>Zoloft take 50mg once in the morning.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Sertraline Hydrochloride Tablets, H10980141</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Idebebone take 30mg three times a day.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Idebenone,H10970363</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deutetrabenazine Oral Tablet [Austedo]</intervention_name>
    <description>The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Deutetrabenazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Genetic diagnosis of Huntington's disease&#xD;
&#xD;
          2. Symptomatic patients with Huntington's disease&#xD;
&#xD;
          3. Disease duration less than 5 years -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1) Movement disorder due to other definite causes instead of Huntington's disease (2)&#xD;
        Severe Lung, kidney or liver disease (3) Neoplastic Disease&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Ying Wu</last_name>
    <role>Study Chair</role>
    <affiliation>Second affiliated Hospital, Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Ying Wu, MD</last_name>
    <phone>0086-571-87783569</phone>
    <email>zhiyingwu@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-Yan Li</last_name>
    <phone>0086-17816872805</phone>
    <email>827011044@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Affiliated Hospital,Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Ying Wu, MD&amp;PhD</last_name>
      <phone>+86-571-87783569</phone>
      <email>zhiyingwu@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Tetrabenazine</mesh_term>
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

